Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180820002

Enrollment

Registered

2018-08-20

Start date

2014-03-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenoma sebaceum

Interventions

0.05% topical everolimus

Experimental Drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -patients with adenoma sebaceum

Exclusion criteria

Exclusion criteria: -pregnancy -allergic reaction to everolimus

Design outcomes

Primary

Measure	Time frame
improvement of adenoma sebaceum 0,4,8,12,24 weeks Photograph	—

Secondary

Measure	Time frame
safety of 0.05% topical everolimus 0,12 weeks blood test for complete blood count ,renal function test	—

Countries

Thailand

Contacts

Public ContactRatchathorn Panchaprateep

Faculty of Medicine, Chulalongkorn University

rpanchaprateep@gmail.com0898923819

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026